Symptomatic Control of Neuroendocrine Tumors with Everolimus

#451

Introduction: Everolimus prolongs progression-free survival, but previous research has not demonstrated its effect on symptoms.

Aim(s): To evaluate the effect of everolimus on symptomatic control of neuroendocrine tumors.

Materials and methods: Fifteen patients with metastatic neuroendocrine disease pre-treated with depot octreotide received combination Everolimus and Octreotide (midgut=8, PNET=3, other=4). Reasons for initiation of Everolimus were progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) (n=5), worsening syndromic symptomatology (n=5), and both (n= 5). Symptomatic response and toxicity were evaluated using standard criteria.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Bainbridge H, Larbi E, Middleton G,

Keywords: neuroendocrine, carcinoid, everolimus, symptom,